IOTherapyEssentials @IOTEssentials

We offer health care provider resources for optimizing Immuno-Oncology (IO) therapy. linktr.ee/iotessentials Global Joined March 2018

Tweets

204
Followers

37
Following

64
Likes

3

IOTherapyEssentials @IOTEssentials

5 years ago

Did you know we have organized our materials by Tumor Type? 🔍 From #CervicalCancer to #Melanoma and #LungCancer, we have a variety of resources to help you take the best possible care of your patients. You can explore them here 👉🏼 bit.ly/tumor-types.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

The #FDA has granted 2 Fast Track designations to cavrotolimod for 2 development programs, including in combination use with anti-PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma. Continue reading here: bit.ly/3dPmEsF.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

Age may not impact outcomes from Metastatic Renal Cell Carcinoma treatment despite increased toxicity in older patients. Find out more at bit.ly/3pR9cXm.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

Cavrotolimod plus PD-1 blockers showing efficacy in advanced cancers, according to the interim results of a Phase 1b/2 clinical trial. Find out more: bit.ly/2ZNQoOo.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

An #immunotherapy agent recently had its #FDA approval pulled from the American market. But this may not be as bad as it sounds, experts say. Find out more at bit.ly/3aQAgBX.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

Two studies have directly linked mechanisms of aging to melanoma spread and treatment resistance. "Recognizing that the age of a patient can affect response to treatment is critical to providing the best care for all patients.” Discover the findings at bit.ly/38PXEyJ.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

Combining two experimental #cancervaccines with #Libtayo, promotes strong anti-tumor immune responses and shows early signs of effectiveness in adults newly diagnosed with #glioblastoma, according to interim data from a Phase 1/2 trial. Read more at bit.ly/3bE00jV.

0 0 1 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

The #FDA has approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo) as a first-line treatment option for patients with locally advanced or metastatic non–small cell #lungcancer (NSCLC) with 50% or more PD-L1 expression: bit.ly/3aHyrGM.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

The combination of brentuximab vedotin and nivolumab demonstrated activity in patients with previously untreated #HodgkinLymphoma who had comorbidities in a phase 2 clinical trial, despite the trial not meeting its prespecified criteria for activity: bit.ly/3ngwXqK.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

“#CheckpointInhibitors have had a significant impact on the way we treat #melanoma. There is a high medical need for immune-activating agents to overcome resistance to checkpoint blockade." Read more at bit.ly/38fYzYu.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"To our knowledge, this is the first reported case of progression on #nivolumab and #cabozantinib when given as sequential monotherapies but stable disease on combination cabozantinib/nivolumab." Find out more at bit.ly/2JN62Fh.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib in patients with advanced renal cell carcinoma." Read more at bit.ly/38epzYo.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"Adjuvant #nivolumab demonstrated clinically meaningful improvements in relapse-free survival, overall survival, and distant metastasis-free survival vs placebo in patients with high-risk #resectedmelanoma." Read more at bit.ly/2XfEf3n.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"The U.S. Food and Drug Administration (#FDA) has approved a new dosing regimen for #Imfinzi (#durvalumab) for the treatment of certain non-small cell lung cancer (NSCLC) and bladder cancer patients." Read more at bit.ly/38gQMcZ.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"#Neoadjuvant treatment with the PD-1 inhibitor #nivolumab demonstrated tolerability in patients with nonmetastatic high-risk clear cell renal cell carcinoma in a phase 1 trial." Find out more at bit.ly/3ohAh5X.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"Despite the use of #checkpointinhibitors in patients with #metastaticmelanoma, an unmet need remains for effective treatments that produce long-lasting responses in this patient population." Find out more at bit.ly/38ih8eA.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"Initial results demonstrate #ENHERTU may be safely combined with #nivolumab, an immune checkpoint inhibitor in patients with HER2 positive or HER2 low metastatic breast cancer." Find out more: bit.ly/3pS9bTv.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"#UvealMelanoma is a relatively rare cancer in general, but the most common cancer of the eye. Tumors arise from the pigment cells, called melanocytes, which reside within the uvea and give color to the eye." Read more at bit.ly/3ohXnJU.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

“A phase I trial is about safety first and foremost, and we now know this treatment is safe and tolerable. But, we also have a strong signal to point us to further study this in head and neck cancer.” Read more at bit.ly/2JLucQm.

0 0 0 0 0

View Details

IOTherapyEssentials @IOTEssentials

6 years ago

"Kintor Pharmaceutical Limited has collected positive data in phase II #clinicaltrials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab/Opdivo) antibody for the second line therapy of advanced hepatocellular carcinoma." Read more at prn.to/3oizn9A.